Originalie
André F et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(6):580–591.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schalhorn, A. Everolimus verlängert das progressionsfreie Überleben. Info Onkol. 17, 10–12 (2014). https://doi.org/10.1007/s15004-014-0965-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15004-014-0965-0